Thermo Fisher Scientific: Overcoming Cell Therapy Manufacturing Challenges with Automation, Scalability, and Process Flexibility
Thursday, May 30, 2024 12:45 PM - 01:45 PM
Room 212-214
Corporate Session
Chair
• David Kuninger, Director, R&D Cell Biology, Thermo Fisher Scientific, USA
Speakers
• Evan Zynda, Senior Scientist, Thermo Fisher Scientific, USA
• Hany Meas, Staff Scientist, Thermo Fisher Scientific, NORWAY
We will present innovative solutions to address challenges throughout the cell therapy manufacturing processes and will introduce a new pluripotent stem cell (PSC) culture system designed for allogeneic applications. Studies demonstrate that defined CD4:CD8 ratios increase the efficacy of T cell therapies, so we expanded our Detachable Dynabeads portfolio to include Detachable Dynabeads that isolate CD4 and CD8 in an automated fashion on the Gibco™ CTS™ DynaCellect™ Magnetic Separation System.
We also took aim at improving downstream expansion with a new, regulatory-friendly culture medium supports more-rapid propagation of early memory T-cells. Combined, these products can close, automate and expedite cell therapy workflows, and improve the safety, efficacy and cost profiles associated.
We will also introduce our new Gibco™ CTS™ StemScale™ PSC Suspension Medium for PSC scale up and highlight the use of this system as input for PSC to iNK cell generation. NK expansion, facilitated by our Gibco™ CTS™ NK-Xpander Medium, characterization, and processing of both iNK and patient derived NK cells will be presented, again highlighting how our innovative solutions help overcome existing cell therapy manufacturing challenges and enable the scale needed for allogeneic applications.
Session Objectives
• Maintaining a defined CD4:CD8 ratio to increase the efficacy of T cell therapies
• How to achieve scalable expansion of PSCs for PSC to iNK cell generation
•How innovative solutions help overcome existing cell therapy manufacturing challenges
• David Kuninger, Director, R&D Cell Biology, Thermo Fisher Scientific, USA
Speakers
• Evan Zynda, Senior Scientist, Thermo Fisher Scientific, USA
• Hany Meas, Staff Scientist, Thermo Fisher Scientific, NORWAY
We will present innovative solutions to address challenges throughout the cell therapy manufacturing processes and will introduce a new pluripotent stem cell (PSC) culture system designed for allogeneic applications. Studies demonstrate that defined CD4:CD8 ratios increase the efficacy of T cell therapies, so we expanded our Detachable Dynabeads portfolio to include Detachable Dynabeads that isolate CD4 and CD8 in an automated fashion on the Gibco™ CTS™ DynaCellect™ Magnetic Separation System.
We also took aim at improving downstream expansion with a new, regulatory-friendly culture medium supports more-rapid propagation of early memory T-cells. Combined, these products can close, automate and expedite cell therapy workflows, and improve the safety, efficacy and cost profiles associated.
We will also introduce our new Gibco™ CTS™ StemScale™ PSC Suspension Medium for PSC scale up and highlight the use of this system as input for PSC to iNK cell generation. NK expansion, facilitated by our Gibco™ CTS™ NK-Xpander Medium, characterization, and processing of both iNK and patient derived NK cells will be presented, again highlighting how our innovative solutions help overcome existing cell therapy manufacturing challenges and enable the scale needed for allogeneic applications.
Session Objectives
• Maintaining a defined CD4:CD8 ratio to increase the efficacy of T cell therapies
• How to achieve scalable expansion of PSCs for PSC to iNK cell generation
•How innovative solutions help overcome existing cell therapy manufacturing challenges
SPONSORED BY:
